How Many Genetic Variants Remain to Be Discovered?

Abstract

A great majority of genetic markers discovered in recent genome-wide association studies have small effect sizes, and they explain only a small fraction of the genetic contribution to the diseases. How many more variants can we expect to discover and what study sizes are needed? We derive the connection between the cumulative risk of the SNP variants to the latent genetic risk model and heritability of the disease. We determine the sample size required for case-control studies in order to achieve a certain expected number of discoveries in a collection of most significant SNPs. Assuming similar allele frequencies and effect sizes of the currently validated SNPs, complex phenotypes such as type-2 diabetes would need approximately 800 variants to explain its 40% heritability. Much smaller numbers of variants are needed if we assume rare-variants but higher penetrance models. We estimate that up to 50,000 cases and an equal number of controls are needed to discover 800 common low-penetrant variants among the top 5000 SNPs. Under common and rare low-penetrance models, the very large studies required to discover the numerous variants are probably at the limit of practical feasibility. Under rare-variant with medium- to high-penetrance models (odds-ratios between 1.6 and 4.0), studies comparable in size to many existing studies are adequate provided the genotyping technology can interrogate more and rarer variants.

Unraveling Genetic Origin of Aging-Related Traits: Evolving Concepts

“…For example, the risk of cardiovascular disease (CVD) in men with an unfavorable risk profile from 45 to 80 years is about 50%, 38 i.e., every other man in such a population will develop CVD over 35 39 High individualized risks imply that the person's genome has an adequate number of the rare risk variants. This number will depend on how strong the effect of an individual allele is; the weaker effect is, the larger number of the risk alleles is required to collectively explain high disease risk in a given person.…”

FDG PET and the genetics of dementia

“…For this type of approach, studying a very large number of subjects is necessary. In fact, whereas several thousand individuals are needed to describe an association with a rare, high-impact variant, the description of a common variant with a low effect requires many thousands of cases and controls [43].…”

Seeing the forest through the gene‐trees

“…[30][31][32][33] Yet to date, after many studies with dense markers, hundreds of these minor contributing genes typically remain unidentified. 34 Complicating this picture is that in searching a chromosomal region implicated by GWAS mapping, we are drawn to genes because it is easy to identify alleles that change an amino acid or disrupt the protein code. But for most normal traits and most complex diseases, with which individuals can live normally for decades, altered timing and level of gene expression may be more important than altered gene structure.…”